OM:HNSABiotechs
Hansa Biopharma (OM:HNSA): Five-Year Losses Worsen as Profitability Targets Face Key Risks
Hansa Biopharma (OM:HNSA) posted another year of widening losses, with net losses expanding at an average annual rate of 11.5% over the past five years, and no sign yet of margin improvement. Shares are currently trading at SEK31.2, considerably below the estimated fair value of SEK503.14, while the company’s price-to-sales ratio of 16.2x stands out against a peer average of 27.1x. Despite ongoing unprofitability, investors are focused on the company’s anticipated revenue growth of 48.4% per...